| Market Capitalization (Millions $) |
1,624 |
| Shares
Outstanding (Millions) |
83 |
| Employees |
143 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-253 |
| Cash Flow (TTM) (Millions $) |
29 |
| Capital Exp. (TTM) (Millions $) |
15 |
Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals Inc. is a NYSDAQ-listed biopharmaceutical company headquartered in New York City, United States of America. The company was previously known as Inotek Pharmaceuticals Corporation but changed its name to Rocket Pharmaceuticals in 2018.
Rocket Pharmaceuticals is focused on the development of innovative gene therapies for rare genetic diseases. The company's pipeline includes a range of gene therapies for hematologic disorders, neurologic disorders, and rare pediatric diseases. The company's lead product candidate is RP-L102, a gene therapy for Fanconi anemia, which is currently in late-stage clinical development.
The company's mission is to provide cures for rare genetic diseases that have no effective treatment options. Rocket Pharmaceuticals aims to develop therapies that offer durable and transformative outcomes for patients, significantly improving their lives and life expectancy. The company's gene therapy platform is built on lentiviral vector technology, which enables the transfer of modified genes into targeted cells, offering the potential to correct genetic mutations.
Rocket Pharmaceuticals leverages the expertise of a team of world-class scientists and researchers with decades of experience in gene therapy development. The company has established partnerships with leading academic institutions, research organizations, and pharmaceutical companies to advance its gene therapy programs.
In addition to its innovative gene therapy development programs, Rocket Pharmaceuticals is committed to advancing patient access to its therapies. The company is focused on building strong relationships with patient advocacy groups, working closely with these organizations to raise awareness of rare genetic diseases and improve patient outcomes.
Overall, Rocket Pharmaceuticals Inc is a leading biopharmaceutical company focused on the development of gene therapies for rare genetic diseases. The company's innovative gene therapy platform and commitment to improving patient outcomes make it a key player in the biotech industry with huge potential to transform the lives of patients around the world.
Company Address: 9 Cedarbrook Drive Cranbury 8512 NJ
Company Phone Number: 659-8001 Stock Exchange / Ticker: NASDAQ RCKT
|
